Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

Phase 1

Terminated

Conditions: Follicular Lymphoma

Interventions: Drug: 90Y-epratuzumab tetraxetan
Biological: veltuzumab

First Posted Date: 2010-06-22

Last Posted Date: 2018-02-22

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 4

Registration Number: NCT01147393

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: thalidomide
Drug: lenalidomide
Biological: rituximab

First Posted Date: 2010-05-18

Last Posted Date: 2022-01-21

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 15

Registration Number: NCT01125176

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Treatment of Polycythemia Vera With Gleevec

Phase 2

Completed

Conditions: Polycythemia Vera

Interventions: Drug: Gleevec

First Posted Date: 2010-05-11

Last Posted Date: 2010-05-17

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 36

Registration Number: NCT01120821

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: azacytidine
Drug: vorinostat

First Posted Date: 2010-05-11

Last Posted Date: 2017-04-10

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 17

Registration Number: NCT01120834

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Phase 1

Terminated

Conditions: Mantle Cell Lymphoma

Interventions: Drug: PD 0332991
Drug: bortezomib

First Posted Date: 2010-04-27

Last Posted Date: 2019-06-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 20

Registration Number: NCT01111188

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Engaging Depressed Low-Income Seniors in Mental Health Services

Not Applicable

Completed

Conditions: Depression

Interventions: Behavioral: ENGAGE

First Posted Date: 2010-03-29

Last Posted Date: 2017-11-08

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 12

Registration Number: NCT01094951

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

Phase 1

Completed

Conditions: Familial Amyotrophic Lateral Sclerosis

Interventions: Drug: Pyrimethamine

First Posted Date: 2010-03-10

Last Posted Date: 2017-06-19

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 32

Registration Number: NCT01083667

Locations: 🇩🇪
Universitäts- und Rehabilitationskliniken Ulm, Ulm, Germany
🇺🇸
Methodist Neurological Institute, Houston, Texas, United States
🇺🇸
Weill Cornell Medical Center/New York Presbyterian Hospital, New York, New York, United States

and more 2 locations

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: lenalidomide
Drug: melphalan

First Posted Date: 2010-01-22

Last Posted Date: 2024-02-01

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 52

Registration Number: NCT01054196

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF

Phase 4

Completed

Conditions: Infertility
Breast Cancer

Interventions: Drug: Letrozole

First Posted Date: 2009-12-18

Last Posted Date: 2022-12-13

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 41

Registration Number: NCT01035099

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis

Completed

Conditions: Batten Disease
Late Infantile Neuronal Ceroid Lipofuscinosis

First Posted Date: 2009-12-18

Last Posted Date: 2020-07-29

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 48

Registration Number: NCT01035424

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy